Truist analyst Joon Lee lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $90 and keeps a Buy rating on the shares.

Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD ...

Equities researchers at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Intellia ...

Intellia Therapeutics reported better-than-expected results for the fourth quarter thanks to a boost in its collaboration ...

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Intellia Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Leerink ...

Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete ...

NEW YORK, NY / ACCESS Newswire / March 3, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to ...

Intellia Therapeutics Inc (NTLA) reports robust pipeline progress and financial stability, despite increased R&D expenses and ...

Intellia Therapeutics (NTLA) stock rises as company delivers promising Q4 2024 results with encouraging pipeline updates.

Fintel reports that on February 28, 2025, JP Morgan downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from ...

Using CRISPR/Cas9 gene-editing technology, Intellia Therapeutics develops gene-editing treatments for genetic diseases. The company's lead programs, NTLA-2001 and NTLA-2002, target transthyretin ...

Full Year 2024 Results Key Financial Results Revenue: US$57.9m (up 60% from ...